chodil
levalbuterol
compar
racem
albuterol
patient
asthma
j
allergi
clin
immunol
xray
xray
e
xacerb
copd
major
caus
morbid
mortal
patient
copd
estim
million
offic
visit
hospit
death
attribut
copd
unit
state
year
great
major
offic
visit
due
copd
exacerb
treat
outpati
set
patient
admit
icu
copd
exacerb
inhospit
mortal
diagnosi
copd
exacerb
consid
increas
dyspnea
increas
sputum
volum
increas
sputum
purul
sever
exacerb
quantifi
assess
magnitud
three
symptom
describ
anthonisen
et
al
type
exacerb
three
symptom
present
type
exacerb
two
three
symptom
present
type
exacerb
one
symptom
one
follow
featur
upper
respiratori
tract
infect
past
day
fever
without
caus
increas
wheez
cough
tachypnea
heart
rate
baselin
chest
radiograph
done
routin
outpati
set
unless
pneumonia
suspect
patient
consid
hospit
admiss
base
sever
initi
symptom
two
retrospect
studi
chest
radiograph
abnorm
report
patient
admit
hospit
copd
exacerb
airway
infect
tracheobronchi
tree
respons
major
exacerb
copd
acut
exacerb
also
associ
increas
bronchial
inflamm
evidenc
influx
sputum
neutrophil
elev
level
myeloperoxidas
elastas
along
increas
level
sputum
cytokin
interleukin
il
tumor
necrosi
leukotrien
b
approxim
exacerb
caus
bacteri
pathogen
viral
infect
remain
exacerb
caus
atyp
pathogen
environment
allergen
exposur
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
three
common
bacteri
pathogen
gramneg
bacilli
like
pseudomona
aeruginosa
may
involv
subset
patient
sever
lung
diseas
atyp
pathogen
like
mycoplasma
pneumonia
chlamydia
pneumonia
may
respons
exacerb
major
goal
treatment
acut
exacerb
copd
prompt
improv
symptom
reduct
relaps
rate
hospit
treatment
option
acut
exacerb
copd
includ
increas
frequenc
inhal
bronchodil
use
oral
steroid
week
select
patient
antibiot
although
role
antibiot
question
result
random
control
trial
demonstr
benefici
effect
use
antibiot
patient
moderatetosever
copd
exacerb
commonli
use
antibiot
also
refer
firstlin
antibiot
includ
amoxicillin
trimethoprimsulfamethoxazol
erythromycin
doxycyclin
newer
antibiot
refer
secondlin
broadspectrum
antibiot
includ
newer
secondgener
thirdgener
cephalosporin
fluoroquinolon
extend
spectrum
macrolid
combin
factor
associ
poor
treatment
outcom
includ
sever
underli
ill
judg
type
exacerb
type
vs
type
type
pathogen
suscept
resist
pattern
host
factor
includ
sever
airflow
obstruct
fev
predict
need
home
oxygen
use
chronic
steroid
therapi
frequenc
exacerb
four
per
year
presenc
comorbid
medic
condit
congest
heart
failur
choic
antibiot
gener
guid
sever
exacerb
presenc
risk
factor
type
pathogen
expect
sever
studi
era
show
differ
treatment
outcom
base
choic
antibiot
howev
great
concern
recent
report
increas
resist
commonli
use
firstlin
antibiot
among
bacteri
pathogen
h
influenza
pneumonia
one
retrospect
studi
use
newer
antibiot
reduc
failur
hospit
rate
compar
firstlin
antibiot
second
studi
treatment
amoxicillin
associ
higher
failur
rate
compar
antibiot
prospect
studi
use
ciprofloxacin
compar
usual
antibiot
patient
moderatetosever
chronic
bronchiti
four
exacerb
associ
improv
outcom
gener
result
multipl
studi
demonstr
patient
lower
fev
valu
requir
intens
therapi
bronchodil
steroid
patient
respond
treatment
prior
episod
acut
exacerb
like
relaps
within
next
day
compar
patient
favor
paramet
optim
treatment
outcom
canadian
chronic
bronchiti
guidelin
suggest
stratifi
patient
copd
exacerb
patient
simpl
chronic
bronchiti
risk
factor
treat
firstlin
narrowspectrum
antibiot
patient
copd
one
risk
factor
treat
newer
secondlin
antibiot
reduc
odd
failur
benefit
use
stratifi
treatment
approach
would
allow
use
less
expens
narrowspectrum
antibiot
patient
simpl
chronic
bronchiti
reserv
expens
secondlin
broadspectrum
antibiot
patient
greater
risk
relaps
hospit
recent
prospect
trial
use
ofloxacin
demonstr
signific
benefit
treatment
copd
exacerb
patient
requir
mechan
ventil
select
use
secondlin
antibiot
could
also
limit
emerg
drugresist
pathogen
although
prospect
random
control
trial
demonstr
canadian
guidelin
effect
usual
care
make
intuit
sens
stratifi
treatment
approach
restrict
use
newer
broadspectrum
antibiot
like
costeffect
benefit
patient
moderatetosever
copd
exacerb
issu
chest
see
page
lieberman
et
al
compar
contrast
clinic
present
infecti
etiolog
patient
pneumonicacuteexacerb
pnae
andnonpneumon
acut
exacerb
npae
copd
patient
admit
hospit
prospect
studi
twentythre
patient
pnae
remain
patient
npae
differ
demograph
data
baselin
spirometri
arteri
blood
ga
level
stabl
state
use
chronic
steroid
therapi
rate
influenza
pneumococc
vaccin
presenc
comorbid
two
group
patient
pnae
group
significantli
higher
rate
abrupt
onset
ill
fever
increas
frequenc
rale
sever
hypoxemia
compar
patient
npae
group
although
clinic
signific
also
trend
toward
higher
frequenc
type
exacerb
three
symptom
pnae
group
vs
surprisingli
pnae
group
higher
rate
admiss
icu
vs
p
need
invas
ventil
vs
p
hospit
day
vs
p
higher
mortal
vs
p
compar
npae
group
sever
aspect
studi
uniqu
studi
merit
discuss
first
foremost
studi
literatur
compar
pnae
vs
npae
copd
second
serolog
diagnost
test
use
exclus
studi
diagnosi
pathogen
viral
bacteri
atyp
bacteri
agent
although
blood
cultur
done
sputum
cultur
respiratori
secret
cultur
perform
furthermor
author
emphas
virtu
serolog
diagnosi
pneumococc
infect
viral
infect
atyp
bacteri
pathogen
studi
incid
viral
atyp
pathogen
high
group
despit
exclus
common
cold
virus
coronaviru
rhinoviru
c
pneumonia
infect
due
technic
difficulti
assay
perhap
data
studi
view
differ
light
use
serolog
offer
altern
option
complimentari
convent
method
make
diagnosi
pathogen
howev
limit
serolog
diagnosi
infecti
caus
well
recogn
literatur
data
serolog
test
retrospect
use
epidemiolog
studi
serolog
gener
help
prospect
manag
patient
communityacquir
pneumonia
recommend
american
thorac
societi
guidelin
third
infecti
etiolog
identifi
patient
pnae
group
compar
patient
npae
group
clearli
much
higher
report
convent
studi
patient
either
communityacquir
pneumonia
acut
exacerb
copd
viral
bacteri
etiolog
significantli
higher
pneumon
group
signific
parainfluenza
viru
type
adenoviru
pnae
group
well
understood
fourth
frequenc
h
influenza
catarrhali
infect
report
serolog
much
lower
studi
compar
literatur
author
acknowledg
limit
serolog
diagnosi
two
pathogen
caution
reader
make
therapeut
decis
base
result
serolog
studi
fifth
incid
atyp
pathogen
legionella
speci
pneumonia
similar
two
group
patient
result
could
differ
c
pneumonia
includ
serolog
sixth
high
incid
mix
pathogen
group
vs
p
signific
conclus
draw
studi
patient
copd
exacerb
demonstr
infiltr
chest
radiograph
wwwchestjournalorg
chest
octob
lump
togeth
patient
without
infiltr
author
take
stand
presenc
infiltr
chest
radiograph
patient
copd
use
exclud
diagnosi
acut
exacerb
copd
two
reason
initi
symptom
increas
dyspnea
increas
sputum
purul
volum
use
differenti
clinic
two
group
except
chest
radiograph
major
patient
treat
outpati
set
chest
radiograph
howev
one
argu
presenc
infiltr
chest
radiograph
key
element
help
differenti
two
group
util
chest
radiograph
patient
suspect
pneumonia
confirm
clinic
impress
determin
extent
radiograph
involv
unilobar
vs
multilobar
identifi
complic
pleural
effus
bronchial
obstruct
result
studi
although
small
clearli
demonstr
wors
outcom
pnae
group
compar
npae
group
higher
morbid
mortal
author
also
attempt
draw
similar
two
group
patient
copd
without
pneumonia
high
rate
atyp
bacteri
pathogen
absenc
signific
differ
incid
mix
infect
emphas
similar
rais
import
specul
question
whether
similar
approach
antibiot
therapi
could
use
two
group
patient
copd
exacerb
given
limit
serolog
studi
design
address
issu
evid
therapeut
decis
made
base
result
studi
studi
design
assess
type
frequenc
infect
serolog
convent
respiratori
cultur
along
document
clinic
risk
factor
treatment
outcom
requir
address
issu
continu
obtain
chest
radiograph
patient
copd
exacerb
pneumonia
suspect
consid
hospit
admiss
confirm
infiltr
chest
radiograph
warrant
treatment
approach
per
american
thorac
societi
guidelin
communityacquir
pneumonia
choic
antibiot
patient
copd
exacerb
absenc
pneumonia
guid
sever
exacerb
presenc
risk
factor
expect
bacteri
pathogen
local
suscept
resist
pattern
omaha
ne
